MARKSANS PHARMA Financial Statement Analysis
|
||
|
The Revenues of MARKSANS PHARMA have increased by 17.56% YoY .
The Earnings Per Share (EPS) of MARKSANS PHARMA has increased by 17.69 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MARKSANS PHARMA Last 5 Annual Financial Results
[BOM: 524404|NSE : MARKSANS]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹2,177 Cr | ₹1,852 Cr | ₹1,491 Cr | ₹1,376 Cr | ₹1,134 Cr |
| Expenses | ₹1,719 Cr | ₹1,513 Cr | ₹1,232 Cr | ₹1,037 Cr | ₹942 Cr |
| Operating Profit (Excl OI) | ₹459 Cr | ₹339 Cr | ₹259 Cr | ₹340 Cr | ₹192 Cr |
| Other Income | ₹50 Cr | ₹59 Cr | ₹42 Cr | ₹6.69 Cr | ₹0.33 Cr |
| Interest | ₹11 Cr | ₹9.13 Cr | ₹8.45 Cr | ₹7.99 Cr | ₹8.75 Cr |
| Depreciation | ₹74 Cr | ₹52 Cr | ₹45 Cr | ₹36 Cr | ₹27 Cr |
| Profit Before Tax | ₹424 Cr | ₹338 Cr | ₹248 Cr | ₹302 Cr | ₹157 Cr |
| Profit After Tax | ₹315 Cr | ₹265 Cr | ₹187 Cr | ₹239 Cr | ₹121 Cr |
| Consolidated Net Profit | ₹314 Cr | ₹266 Cr | ₹185 Cr | ₹236 Cr | ₹117 Cr |
| Earnings Per Share (Rs) | ₹6.92 | ₹5.88 | ₹4.51 | ₹5.76 | ₹2.86 |
| PAT Margin (%) | 13.75 | 13.01 | 12.06 | 17.14 | 10.65 |
| ROE(%) | 16.53 | 18.59 | 18.72 | 31.33 | 20.49 |
| ROCE(%) | 22.40 | 22.89 | 23.82 | 39.76 | 25.57 |
| Total Debt/Equity(x) | 0.01 | 0.02 | 0.04 | 0.02 | 0.03 |
Key Financials |
||
| Market Cap | : | ₹ 10,076.9 Cr |
| Revenue (TTM) | : | ₹ 2,474.4 Cr |
| Net Profit(TTM) | : | ₹ 369.5 Cr |
| EPS (TTM) | : | ₹ 8.2 |
| P/E (TTM) | : | 27.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MARKSANS PHARMA | -2.6% | 1.2% | 55.5% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.8% | 7.6% | 8.4% |
| DIVIS LABORATORIES | -2.3% | 0.8% | 72.7% |
| CIPLA | -5.4% | -1.5% | 0.8% |
| TORRENT PHARMACEUTICALS | -0.8% | 6.8% | 25.6% |
| DR REDDYS LABORATORIES | -5.5% | 1.6% | -5.1% |
| MANKIND PHARMA | 2.1% | 3.7% | 9.5% |
| ZYDUS LIFESCIENCES | -4.4% | 0.4% | -12.5% |
| LUPIN | -4.5% | 6.9% | 25.2% |
MARKSANS PHARMA Revenues
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | 17.56 % |
| 5 Yr CAGR | 17.71 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,177 Cr | 17.56 | |
| Mar2023 | ₹1,852 Cr | 24.23 | |
| Mar2022 | ₹1,491 Cr | 8.33 | |
| Mar2021 | ₹1,376 Cr | 21.33 | |
| Mar2020 | ₹1,134 Cr | - | |
MARKSANS PHARMA Operating Profit
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | 35.15 % |
| 5 Yr CAGR | 24.28 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹459 Cr | 35.15 | |
| Mar2023 | ₹339 Cr | 31.07 | |
| Mar2022 | ₹259 Cr | -23.77 | |
| Mar2021 | ₹340 Cr | 76.65 | |
| Mar2020 | ₹192 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 14.96 % |
| 5 Yr CAGR | 5.58 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 21.06% | 14.96 | |
| Mar2023 | 18.32% | 5.53 | |
| Mar2022 | 17.36% | -29.66 | |
| Mar2021 | 24.68% | 45.60 | |
| Mar2020 | 16.95% | - | |
MARKSANS PHARMA Profit After Tax
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | 17.80 % |
| 5 Yr CAGR | 27.96 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹314 Cr | 17.80 | |
| Mar2023 | ₹266 Cr | 44.29 | |
| Mar2022 | ₹185 Cr | -21.77 | |
| Mar2021 | ₹236 Cr | 101.62 | |
| Mar2020 | ₹117 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 5.69 % |
| 5 Yr CAGR | 6.60 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 13.75 % | 5.69 | |
| Mar2023 | 13.01 % | 7.88 | |
| Mar2022 | 12.06 % | -29.64 | |
| Mar2021 | 17.14 % | 60.94 | |
| Mar2020 | 10.65 % | - | |
MARKSANS PHARMA Earnings Per Share (EPS)
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | 17.69 % |
| 5 Yr CAGR | 24.72 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹6.92 | 17.69 | |
| Mar2023 | ₹5.88 | 30.38 | |
| Mar2022 | ₹4.51 | -21.70 | |
| Mar2021 | ₹5.76 | 101.40 | |
| Mar2020 | ₹2.86 | - | |
MARKSANS PHARMA Return on Capital Employed (ROCE)
[BOM: 524404|NSE : MARKSANS]
| Y-o-Y | -2.14 % |
| 5 Yr CAGR | -3.25 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 22.4% | -2.14 | |
| Mar2023 | 22.89% | -3.90 | |
| Mar2022 | 23.82% | -40.09 | |
| Mar2021 | 39.76% | 55.49 | |
| Mar2020 | 25.57% | - | |
MARKSANS PHARMA Share Price vs Sensex
| Current Share Price | : | ₹222.4 |
| Current MarketCap | : | ₹ 10,076.9 Cr |
| Updated EOD on | : | Mar 28,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MARKSANS PHARMA | -2.6% |
1.2% |
55.5% |
| SENSEX | 0.7% |
4% |
6.3% |
MARKSANS PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 1.5% | 3.4% | 7.5% |
| BSE MIDSMALLCAP | -1.1% | 3.4% | 8.1% |
| BSE SMALLCAP | -1.4% | 3.1% | 9% |
| BSE HEALTHCARE | -1.7% | 5% | 20.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | 0.2% | 4.1% | 6.8% |
| NIFTY MICROCAP 250 | -3.2% | 0.9% | 9.2% |
You may also like the below Video Courses
FAQ about MARKSANS PHARMA Financials
How the annual revenues of MARKSANS PHARMA have changed ?
The Revenues of MARKSANS PHARMA have increased by 17.56% YoY .
How the Earnings per Share (EPS) of MARKSANS PHARMA have changed?
The Earnings Per Share (EPS) of MARKSANS PHARMA has increased by 17.69 % YoY .
Check out Intrinsic Value of Peers of MARKSANS PHARMA
Compare Stock Analytics of Peers of MARKSANS PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
